Your revenue estimates and market cap are very good. However, there is a 7.5% difference (using your figures) in the Cap/rev(est) ratios for the two companies. Hence, for GILD to be traded like DNA shares on the Cap/Rev basis it should be @ $58.27, $4 above Friday's close. Genentech is a strong and good company, and it can 'buy' any breakthrough ideas now. Nothing wrong for GILD to buy some.